Alexandria Hammond
Stock Analyst at B of A Securities
(2.74)
# 1,580
Out of 5,182 analysts
15
Total ratings
72.73%
Success rate
14.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $570 → $529 | $520.09 | +1.71% | 3 | Feb 20, 2026 | |
| ABBV AbbVie | Downgrades: Peer Perform | n/a | $197.38 | - | 2 | Jan 8, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $135 | $110.23 | +22.47% | 2 | Jan 8, 2026 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $744.44 | +54.48% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $26.79 | -6.68% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $48.70 | -17.86% | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $868.27 | +15.17% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $225.34 | -15.68% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $127.75 | -13.89% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $57.78 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $180.67 | - | 1 | Nov 15, 2024 |
Madrigal Pharmaceuticals
Feb 20, 2026
Maintains: Neutral
Price Target: $570 → $529
Current: $520.09
Upside: +1.71%
AbbVie
Jan 8, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $197.38
Upside: -
Merck & Co.
Jan 8, 2026
Upgrades: Outperform
Price Target: $135
Current: $110.23
Upside: +22.47%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $744.44
Upside: +54.48%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $26.79
Upside: -6.68%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $48.70
Upside: -17.86%
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $868.27
Upside: +15.17%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $225.34
Upside: -15.68%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $127.75
Upside: -13.89%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $57.78
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $180.67
Upside: -